239 related articles for article (PubMed ID: 2961354)
1. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
2. Clodronate in the medical management of hyperparathyroidism.
Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man.
McCloskey EV; Yates AJ; Beneton MN; Galloway J; Harris S; Kanis JA
Bone; 1987; 8 Suppl 1():S35-41. PubMed ID: 2825741
[TBL] [Abstract][Full Text] [Related]
4. Dichloromethylene diphosphonate action in hematologic and other malignancies.
Canfield RE; Siris ES; Jacobs TP
Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
[TBL] [Abstract][Full Text] [Related]
5. Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.
Ralston SH; Gardner MD; Jenkins AS; McKillop JH; Boyle IT
Bone Miner; 1987 May; 2(3):227-42. PubMed ID: 2974309
[TBL] [Abstract][Full Text] [Related]
6. Effects of clodronate on immobilization bone loss.
Minaire P; Depassio J; Berard E; Meunier PJ; Edouard C; Pilonchery G; Goedert G
Bone; 1987; 8 Suppl 1():S63-8. PubMed ID: 2961357
[TBL] [Abstract][Full Text] [Related]
7. Management of hypercalcemia in relation to pathophysiology.
Bonjour JP; Rizzoli R; Hirschel-Scholz S; Caverzasio J
Bone; 1987; 8 Suppl 1():S29-33. PubMed ID: 2825740
[TBL] [Abstract][Full Text] [Related]
8. [Monotherapy with clodronate for tumor-induced hypercalcemia].
Harjung H; Fritze D
Dtsch Med Wochenschr; 1990 Jan; 115(2):48-52. PubMed ID: 2136827
[TBL] [Abstract][Full Text] [Related]
9. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
[TBL] [Abstract][Full Text] [Related]
10. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
11. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
12. Treatment of malignant hypercalcaemia with clodronate.
Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
[TBL] [Abstract][Full Text] [Related]
13. Bone resorption and renal calcium reabsorption in renal cell carcinoma-bearing mice: the effects of bisphosphonate.
Weissglas M; Löwik C; Schamhart D; Theuns H; Kurth KH; Papapoulos S
BJU Int; 2007 Jun; 99(6):1530-3. PubMed ID: 17428243
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of tumor hypercalcemia with clodronate. Effect on parathormone and calcitriol].
Scharla SH; Minne HW; Sattar P; Mende U; Blind E; Schmidt-Gayk H; Wüster C; Ho T; Ziegler R
Dtsch Med Wochenschr; 1987 Jul; 112(28-29):1121-5. PubMed ID: 2956079
[TBL] [Abstract][Full Text] [Related]
15. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hypercalcaemia of malignancy with clodronate.
Bonjour JP; Rizzoli R
Bone; 1991; 12 Suppl 1():S19-23. PubMed ID: 1835397
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of calcitonin and clodronate in hypercalcaemia.
Ljunghall S; Rastad J; Akerström G
Bone; 1987; 8 Suppl 1():S79-83. PubMed ID: 2961359
[TBL] [Abstract][Full Text] [Related]
18. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
19. Humoral hypercalcaemia of malignancy: metabolic and histomorphometric studies during surgical management of the primary tumour.
Ralston SH; Boyce BF; Cowan RA; Gardner MD; Dryburgh FJ; Boyle IT
Q J Med; 1986 Mar; 58(227):325-35. PubMed ID: 3016790
[TBL] [Abstract][Full Text] [Related]
20. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
